Depletion of cardiac norepinephrine but not brain catecholamines by MPTP-N-oxide in mice.
After a single dose in mice, MPTP-N-oxide caused a dose-dependent depletion of cardiac norepinephrine which was similar although less pronounced than that caused by MPTP itself. After repeated daily doses, MPTP-N-oxide depleted cardiac norepinephrine, but did not deplete norepinephrine in the frontal cortex or dopamine in the striatum of mice. MPTP-N-oxide differed from MPTP, which depleted cardiac norepinephrine, cortical norepinephrine and striatal dopamine after repeated daily doses, but was similar to MPP+, another metabolite of MPTP, which depleted only cardiac norepinephrine. These data suggest that MPTP-N-oxide may contribute to the peripheral catecholamine-depleting effects after MPTP injection.
Hemrick-Luecke
S K
SK
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
Robertson
D W
DW
Fuller
R W
RW
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000031:analogs & derivatives* / Q000494:pharmacology; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002395:Catecholamines / Q000378:metabolism*; D003497:Cyclic N-Oxides / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009206:Myocardium / Q000378:metabolism*; D009638:Norepinephrine / Q000378:metabolism*; D009928:Organ Specificity; D012016:Reference Values
D002395:Catecholamines; D003497:Cyclic N-Oxides; D015102:3,4-Dihydroxyphenylacetic Acid; C065885:1-methyl-4-phenyl-1,2,3,6-(tetrahydropyridine)-N-oxide; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid